Survival of pulmonary arterial hypertension related to systemic sclerosis: a 3-year nationwide longitudinal study Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008
Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis Source: Eur Respir J 2016; 48: 1658-1667 Year: 2016
Incidence of pulmonary arterial hypertension related to systemic sclerosis: a 3-year nationwide longitudinal study Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008
Long-term follow-up of patients with pulmonary sarcoidosis Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018
Incidence of new pulmonary hypertension and determining factors during follow-up of patients with systemic sclerosis after negative right heart catheterisation Source: International Congress 2017 – PAH and CTEPH Year: 2017
Clinical-radiological and functional follow-up of pulmonary sequelae after COVID-19 Source: Virtual Congress 2021 – Chronic COVID - 19 Year: 2021
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018
Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis Source: Eur Respir J, 54 (2) 1900586; 10.1183/13993003.00586-2019 Year: 2019
Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018 Year: 2019
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Hemodynamic phenotypes in systemic sclerosis patients screened for pulmonary hypertension – impact of the new PH-definition Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1800678; 10.1183/13993003.00678-2018 Year: 2018
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
Acute effects, 1-year, and 2-year follow up of iloprost-aerosol therapy in severe primary pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018
Efficacy of epoprostenol treatment for pulmonary hypertension: hemodynamic and clinical improvement during the initial 8-month period Source: Eur Respir J 2001; 18: Suppl. 33, 325s Year: 2001
Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001
Predictors of pulmonary artery hypertension in patients with systemic sclerosis Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012